My SciELO
Services on Demand
Journal
Article
Indicators
-
Cited by SciELO
-
Access statistics
Related links
-
Cited by Google
-
Similars in SciELO
-
Similars in Google
Share
Revista Española de Enfermedades Digestivas
Print version ISSN 1130-0108
Rev. esp. enferm. dig. vol.109 n.8 Madrid Aug. 2017
https://dx.doi.org/10.17235/reed.2017.4874/2017
LETTERS TO THE EDITOR
Chronic diarrhea, weight loss and heart failure. Features of the same disease?
Diarrea crónica, síndrome constitucional e insuficiencia cardiaca. ¿Manifestaciones de una misma entidad?
Key words: Tumor. Carcinoid. Metastasis.
Palabras clave: Tumor. Carcinoide. Metástasis.
Dear Editor,
Carcinoid tumors are neoplasm that release hormone-like substances. They can produce liver metastasis and present with symptoms of the carcinoid syndrome.
A 78 year old man presented with a history of chronic diarrhea, weight loss and shortness of breath. The physical examination revealed a red facial flush, hepatomegaly and a systolic heart murmur. Multiple liver lesions were found on abdominal ultrasound. The abdominal computed tomography (CT) showed evidence of liver metastases and a tumor in the ileum with lymph node infiltration (Fig. 1). A fine needle puncture aspiration of the liver was performed and was compatible with a carcinoid tumor. The octreoscan showed areas of uptake in the liver and ileum. The echocardiography indicated carcinoid-related tricuspid valve disease with severe tricuspid regurgitation that required early surgical treatment. The patient was treated symptomatically with somatostatin analogs with a good response.
Discussion
Carcinoid tumors are mainly located in the small bowel (1). They can be asymptomatic or produce symptoms due to tumor bulk such as intestinal obstruction or bleeding. In addition, they can produce the carcinoid syndrome. This includes red facial flush, diarrhea, wheezing and valvular heart disease. This is unusual and is associated with increased morbidity and mortality, requiring an early surgical intervention (2).
In those patients with clinical suspicion of carcinoid syndrome, the measurement of urinary 5-HIAA levels is used to confirm the diagnosis (3). Imaging tests such as the octreoscan, magnetic resonance imaging (MRI) or CT scan with oral contrast are required for localization of both primary lesions and metastasis (4).
Somatostatin-analogue therapies such as the octreotide are given for symptomatic relief. Surgical resection of the tumor is the only curative therapy and must be performed if there is no evidence of metastatic disease.
María Megía-Sánchez, Carmen Poves-Francés and Enrique Rey-Díaz-Rubio
Department of Digestive Diseases. Hospital Clínico San Carlos University Hospital. Madrid, Spain
References
1. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89:15. DOI: 10.1002/jso.20179. [ Links ]
2. Roberts WC. A unique heart disease associated with a unique cancer: Carcinoid heart disease. Am J Cardiol 1997;80:25. DOI: 10.1016/S0002-9149(97)00340-8. [ Links ]
3. Zandee W, Kamp K, Van Adrichem RC, et al. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumors. Eur J Endocrinol 2016. DOI: 10.1530/EJE-16-0392. [ Links ]
4. Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol 2016;34(6):588-96. DOI: 10.1200/JCO.2015.64.0987. [ Links ]